Biotech Values

[oc631]

If i were a GT3 patient, i'd still rather try the 12-weeks Sofo/Riba oral treatment first, knowing no resistance to sofo jeopardize my future treatment options in case i relapse.

The point I'm trying to make is SOC and Sofo/Riba both stink in GT3. Strong resistance profiles become extra important in combos that don't work that well. Since Sofo/Riba is 7% less effective than existing SOC (according to the latest study) GILD should be open to testing the daclatasvir/sofosbuvir combo for the 7% of the patient population with this genotype.

Once the Sofo/Riba GT3 treatment-experienced data comes in it will be clear that less than half the GT3 patients treated with this combo will achieve a SVR. This means every other patient will be a treatment-failure. Meanwhile GT1 and GT2 SVR rates are looking to be over 90% in all subgroups.